FDA 483 - Noble Pharma, LLC

An FDA inspection of Noble Pharma LLC in Menomonie, WI, from March 3-6, 2025, revealed significant deficiencies in drug manufacturing processes. Observations included a lack of validation for equipment, processes, and container closure, inadequate facility configuration to prevent contamination, and insufficient computer system controls. These issues indicate a failure to ensure product quality and integrity.